Dechra Pharmaceuticals PLC — Share Issue/Capital Change 2019

Aug 30, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7325K

Dechra Pharmaceuticals PLC

30 August 2019

30 August 2019

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

Additional Listing

An application for admission to the Premium Segment of the Official List has been made to the Financial Conduct Authority and the London Stock Exchange for an increase of 133,129 ordinary shares of 1 pence each in relation to the existing block listing (the Shares) for the Company's following schemes:

·      Save As You Earn: 30,000;

·      Long-Term Incentive Scheme: 103,129.

These Shares will rank pari passu with the Company's existing shares in issue.  It is expected that admission will become effective on or around 3 September 2019.

For further information, please contact:

Dechra Pharmaceuticals PLC

Melanie Hall, Company Secretary

Telephone number:  +44 (0) 1606 814730

Email: corporate.enquiries@dechra.com 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com.

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ALSLLFSITSIIVIA